Dec 01, 2021 / 01:30PM GMT
Operator
Good day, and thank you for standing by. Welcome to the Vertex Pharmaceuticals VX-147 Phase II Results Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. (Operator Instructions) I would now like to hand the conference over to your speaker today, Michael Partridge, Senior Vice President of Investor Relations. Please go ahead.
Michael Partridge - Vertex Pharmaceuticals Incorporated - SVP of IR
Good morning. We look forward to discussing with you today our APOL1 program and our VX-147 Phase II results. On the call, making prepared remarks, we have Dr. Reshma Kewalramani, Vertex's CEO and President; and Dr. David Altshuler, Vertex's Chief Scientific Officer.
We recommend that you access the webcast slides as you listen to this call. These slides provide context for understanding the role of APOL1 in kidney disease and also depict the Phase II data in more detail. This call is being recorded. A replay will be available on our website.
We will make
Vertex Pharmaceuticals Inc to Discuss VX-147 Phase 2 Clinical Results Call Transcript
Jan 23, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers